Volanesorsen

Volanesorsen has been studied in 4 papers since 2025: none in people yet, 4 reviews; 4 in the past year. No study of it in people or animals has been published yet. The newest paper, Oct 26, 2026: “Targeting Apolipoprotein C-III in Hypertriglyceridemia: Implications for Pancreatitis and Cardiovascular risk”.

4 papers study it1 findingUpdated Oct 26, 2026

At a glance

The findings reach people, from one lab or study. 1 lab in 2 countries.

Studies of volanesorsen measured 1 outcome; the most studied are LDL cholesterol (1 study).

LDL cholesterol

upin humans1

1 study

Volanesorsen increases LDL cholesterol in humans (severe hypertriglyceridemia) (MD +62.74, p=0.004).
“Volanesorsen was linked to higher low-density lipoprotein-cholesterol (MD: +62.74; p=0.004).”
Reviewsevere hypertriglyceridemia
Efficacy and safety of antisense oligonucleotide therapies targeting APoC-III in patients with severe hypertriglyceridemia: a meta-analysis of randomized controlled trials
Monaldi archives for chest disease = Archivio Monaldi per le malattie del toraceFeb 23, 2026